RU 486

Paper Summary:

The development of the pharmaceutical drug RU486 by French company Groupe Roussel UCLAF in 1998 sparked a wave of controversy as a result of its implications in the early termination of pregnancy. This paper examines the major problems that the makers of "RU 486" faced in obtaining approval for public use and considers the opportunities available for the pharmaceutical giant. In addition, a brief discussion of the stigma surrounding abortion is presented to explain why problems exist with the development of such drugs. Finally, a needs assessment is identified and subsequent solutions are presented to the RU 486 dilemma.

From the Paper:

"Perhaps the first step in establishing solutions to the population crisis is to identify the long-term effects of such drugs as RU 486 in order to make them more attractive to the regulators of the pharmaceutical industry, including the FDA and equivalent bodies in other countries. As soon as these effects have been identified, it will likely be more feasible for such governing bodies to determine if these drugs are an effective alternative for the general public. Furthermore, pharmaceutical firms must continue to develop groundbreaking research and techniques that will assist in predicting fertility and other outcomes related to the human condition, regardless of the pressure placed on them by interest groups. Finally, governing bodies and pharmaceuticals must work together in developing methods that will provide the general public with many options for controlling their own fertility, including but not limited to RU 486 and other contraceptive methods."

More papers on RU 486:

• Case Study # 69990 : "RU 486"
• Analytical Essay # 54183 : "RU-486"
• Persuasive Essay # 27846 : "Abortion: Ethical and Political Issues of RU 486"

APA Citation:

MLA Citation: